Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Equity Average (2019 - 2025)

Cyclerion Therapeutics has reported Equity Average over the past 7 years, most recently at $9.1 million for Q3 2025.

  • Quarterly results put Equity Average at $9.1 million for Q3 2025, up 6.64% from a year ago — trailing twelve months through Sep 2025 was $9.1 million (up 6.64% YoY), and the annual figure for FY2024 was $10.1 million, down 7.37%.
  • Equity Average for Q3 2025 was $9.1 million at Cyclerion Therapeutics, up from $8.7 million in the prior quarter.
  • Over the last five years, Equity Average for CYCN hit a ceiling of $60.8 million in Q3 2021 and a floor of $4.5 million in Q2 2023.
  • Median Equity Average over the past 5 years was $10.6 million (2024), compared with a mean of $22.6 million.
  • Biggest five-year swings in Equity Average: crashed 85.46% in 2023 and later surged 106.13% in 2024.
  • Cyclerion Therapeutics' Equity Average stood at $52.3 million in 2021, then tumbled by 74.22% to $13.5 million in 2022, then dropped by 10.44% to $12.1 million in 2023, then fell by 29.44% to $8.5 million in 2024, then rose by 6.22% to $9.1 million in 2025.
  • The last three reported values for Equity Average were $9.1 million (Q3 2025), $8.7 million (Q2 2025), and $8.8 million (Q1 2025) per Business Quant data.